Prof Andrew Armstrong speaks to ecancer about the final overall survival analysis from ARCHES: A phase III, randomised, double-blind, placebo-controlled study of enzalutamide + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer.
Initially, Prof Armstrong explains the background of the ARCHES study. He says enzalutamide and ADT reduced risk of radiographic progression and improved secondary outcomes in men with mHSPC over placebo plus ADT. This study reported the final overall survival, a key secondary endpoint in ARCHES and a critical benchmark of clinical efficacy. He then talks about the study design and key results.
The study demonstrates that enzalutamide plus ADT significantly prolongs survival in men with mHSPC. Prof Armstrong concludes by mentioning how the results form this study can impact the future treatment of metastatic hormone-sensitive prostate cancer.
Read more on the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.